Processa Pharmaceuticals, Inc. — Director's Dealing 2022

Oct 3, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2022-09-30

Reporting Person: Young David (Director, President & CEO, 10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-09-30	Restricted Stock Units	$0	A	25350	Acquired		Common Stock (25350)	Direct

Footnotes

F1: Each Restricted Stock Unit represents a contingent right to receive one share of the lessee's common stock upon the earliest of termination of employment, the third anniversary of the award date, a change of control, or the reporting person's death.